Not applicableStudy completedNCT03133234What this trial is testingEffect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLCWho this might be right forT790M Positive NSCLC Patients AstraZeneca 47
Testing effectiveness (Phase 2)Study completedNCT01858389What this trial is testingDacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Pfizer 41
Not applicableWithdrawnNCT03519958What this trial is testingEpidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong KongWho this might be right forNon-small Cell Lung Cancer AstraZeneca
Testing effectiveness (Phase 2)UnknownNCT03502850What this trial is testingSafety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung CancerWho this might be right forLocally Advanced or Metastatic NSCLC Jiangsu Aosaikang Pharmaceutical Co., Ltd. 507
Not applicableActive Not RecruitingNCT01754025What this trial is testingINHERIT EGFR - Studying Germline EGFR MutationsWho this might be right forLung Cancer Dana-Farber Cancer Institute 121
Not applicableWithdrawnNCT02368990What this trial is testingT790M Mutation Positive 2nd Line STandard of cAre RegistryWho this might be right forNon Small Cell Lung Cancer AstraZeneca
Not applicableLooking for participantsNCT06573073What this trial is testingEvaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M MutationWho this might be right forNon Small Cell Lung CancerEGFR T790M LifeOS Genomics Corporation 300
Large-scale testing (Phase 3)Study completedNCT02959749What this trial is testingOsimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung CancerWho this might be right forProgression Free Survival Qingdao Central Hospital 147
Testing effectiveness (Phase 2)Ended earlyNCT02454842What this trial is testingStudy for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) PatientsWho this might be right forNon-small Cell Lung CancerNSCLCNon-squamous NSCLC Rain Oncology Inc 21
Not applicableUnknownNCT03532698What this trial is testingCombination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)Who this might be right forNon-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 100
Testing effectiveness (Phase 2)UnknownNCT02811354What this trial is testingPhase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNAWho this might be right forCarcinoma, Non-Small-Cell Lung National University Hospital, Singapore 108
Not applicableStudy completedNCT03137264What this trial is testingResistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive PatientsWho this might be right forNon-small Cell Lung Cancer AstraZeneca 44
Testing effectiveness (Phase 2)Study completedNCT01802632What this trial is testingAZD9291 First Time In Patients Ascending Dose StudyWho this might be right forAdvanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer AstraZeneca 603
Large-scale testing (Phase 3)UnknownNCT01579630What this trial is testingGenius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line TherapyWho this might be right forNSCLC Taipei Veterans General Hospital, Taiwan 52
Not applicableEnded earlyNCT03053297What this trial is testingObservational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)Who this might be right forCarcinoma, Non-Small-Cell Lung AstraZeneca 89
Testing effectiveness (Phase 2)Study completedNCT03758287What this trial is testingNingetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M NegativeWho this might be right forNon-small Cell Lung Cancer Sunshine Lake Pharma Co., Ltd. 108
Testing effectiveness (Phase 2)UnknownNCT03257124What this trial is testingStudy of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMSWho this might be right forNon-Small Cell Lung Cancer With EGFR T790M MutationWith Brain and/or Leptomeningeal MetastasisFailed Tyrosine Kinase Inhibitors Samsung Medical Center 80
Testing effectiveness (Phase 2)Looking for participantsNCT06706076What this trial is testingBH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 MutationsWho this might be right forNSCLC (Advanced Non-small Cell Lung Cancer) BlossomHill Therapeutics 675
Testing effectiveness (Phase 2)UnknownNCT04029350What this trial is testingStudy of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790MWho this might be right forNon Small Cell Lung Cancer Tianjin Medical University Cancer Institute and Hospital 53
Not applicableStudy completedNCT02777658What this trial is testingPANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLCWho this might be right forCarcinoma, Non-Small-Cell Lung AstraZeneca 169